Retina Consultants of America Physicians to Present Groundbreaking Clinical Research and Trial Data at ASRS 2026
Retina Consultants of America (RCA), one of the largest retina physician networks in the United States, has announced that specialists from across its nationwide affiliated practices will showcase an extensive portfolio of clinical research, innovative surgical techniques, real-world evidence, and emerging treatment strategies during the American Society of Retina Specialists (ASRS) 44th Annual Meeting, taking place from July 15–18, 2026.
With physicians participating in more than 30 scientific sessions, RCA’s presence at this year’s conference underscores the organization’s growing role in advancing retinal disease research and improving patient care through scientific collaboration. The presentations span a broad spectrum of ophthalmic innovation, including late-breaking clinical trial findings, gene therapy research, artificial intelligence applications, surgical advancements, and new approaches to managing both common and rare retinal diseases.
The ASRS Annual Meeting is widely regarded as one of the most influential scientific gatherings for retina specialists worldwide, bringing together clinicians, researchers, and industry leaders to discuss the latest developments in vitreoretinal medicine. RCA’s significant participation highlights its commitment to accelerating research that may ultimately improve vision outcomes for patients affected by complex retinal disorders.
Broad Scientific Program Highlights Emerging Retina Therapies
Among the research presentations are several late-breaking abstracts featuring data from ongoing clinical studies designed to address some of the most challenging retinal diseases currently affecting millions of patients worldwide.
One of the featured studies focuses on investigational gene therapy for neovascular age-related macular degeneration (AMD), one of the leading causes of irreversible vision loss among older adults. Researchers will present new findings evaluating the potential of gene-based treatment strategies to provide longer-lasting therapeutic benefits while reducing the burden associated with repeated intravitreal injections.
Another important presentation examines comparative data involving anti-complement therapies and their effects on retinal nerve fiber layer thickening. Understanding these structural retinal changes could help physicians better evaluate treatment responses and optimize care for patients receiving complement-inhibiting therapies.
The scientific program will also include the first Phase 3 clinical trial outcomes for a novel long-duration anti-vascular endothelial growth factor (anti-VEGF) therapy designed for individuals with diabetic retinopathy. Long-acting anti-VEGF agents have become an area of intense clinical interest because they may reduce treatment frequency while maintaining effective disease control.
Together, these presentations reflect the rapid pace of innovation occurring across retinal medicine and demonstrate the increasing role of advanced therapeutics in preserving vision.
Commitment to Advancing Retina Care
According to Charles C. Wykoff, MD, PhD, FASRS, Director of Research at Retina Consultants of Texas and Chair of Research at Retina Consultants of America, the breadth of research being presented reflects the collaborative efforts taking place across RCA-affiliated practices.
He noted that the presentations highlight the organization’s ongoing commitment to developing innovative therapies and improving disease management strategies that can help preserve and restore vision for patients living with retinal diseases.
The collaborative nature of RCA’s research network enables physicians from multiple practices to contribute expertise, patient populations, and scientific insights that strengthen clinical studies while accelerating the development of new treatment approaches.
Physicians from Fifteen Affiliated Practices to Share Research
The scientific sessions feature presentations led by retina specialists representing 15 RCA-affiliated practices throughout the United States.
These physicians have contributed research across numerous areas of retinal medicine, including:
- Clinical trial investigations
- Surgical innovations
- Medical retina therapies
- Artificial intelligence applications
- Pediatric retinal diseases
- Ocular oncology
- Retinal imaging
- Real-world treatment outcomes
- Rare inherited retinal disorders
- Retinal detachment management
By bringing together expertise from multiple institutions, RCA continues to strengthen collaboration among retina specialists while supporting the translation of research findings into clinical practice.
Advancing the Next Generation of Retinal Therapies
One of the major themes highlighted during the meeting centers on the development of next-generation treatments for retinal diseases.
Researchers will present findings involving emerging therapies that seek to improve treatment durability, reduce patient burden, and enhance long-term visual outcomes.
Among the featured research topics is an investigational study evaluating suprachoroidal delivery of gene therapy for diabetic retinopathy.
Suprachoroidal administration represents an innovative method of delivering therapeutic agents into a targeted layer of the eye, potentially improving drug distribution while minimizing exposure to surrounding tissues.
Gene therapy continues to generate significant interest across ophthalmology because it offers the possibility of producing sustained therapeutic effects following a single treatment rather than requiring repeated injections.
Investigators hope these technologies may eventually transform the management of chronic retinal diseases by providing longer-lasting disease control.
Artificial Intelligence Continues Expanding in Retina Care
Artificial intelligence is becoming an increasingly valuable tool within ophthalmology, and several RCA presentations explore how AI may enhance clinical decision-making.
One presentation examines the use of artificial intelligence to predict the location of retinal tears in patients with rhegmatogenous retinal detachment.
Accurately identifying retinal tears is essential because untreated retinal detachments can result in permanent vision loss. AI-assisted imaging analysis may help physicians detect pathology more efficiently while supporting earlier intervention.
Researchers are also investigating how machine learning algorithms can analyze retinal imaging data to identify subtle disease patterns that may not be immediately apparent during routine examination.
As AI technologies continue evolving, they are expected to complement physician expertise by improving diagnostic accuracy, workflow efficiency, and individualized treatment planning.
Surgical Innovation Remains a Major Focus
In addition to medical therapies, RCA physicians will present several studies focused on advancing vitreoretinal surgical techniques.
Among these presentations are new approaches for repairing extra-large and XX-large macular holes.
Macular holes are full-thickness defects in the central retina that can significantly impair detailed vision. While surgical techniques have improved considerably over recent decades, treating very large macular holes remains technically challenging.
Researchers will discuss innovative surgical methods that may improve closure rates and visual recovery for patients with these complex conditions.
These advancements reflect ongoing efforts to refine vitreoretinal surgery while expanding treatment options for patients previously considered difficult to manage.
Research Addressing Rare and Complex Retinal Disorders
Beyond common retinal diseases such as diabetic retinopathy and age-related macular degeneration, RCA physicians will also share findings involving several uncommon but clinically significant conditions.
These include research related to:
Pediatric Retinal Diseases
Children with inherited or developmental retinal disorders often require specialized diagnostic and treatment approaches. Investigators will present new findings aimed at improving care for younger patients with vision-threatening retinal diseases.
Ocular Oncology
Research involving tumors affecting the retina and surrounding ocular structures will explore advances in diagnosis, monitoring, and treatment strategies designed to preserve both vision and overall eye health.
Stickler Syndrome
Several presentations examine retinal detachment occurring in patients with Stickler syndrome, a rare inherited connective tissue disorder associated with an increased lifetime risk of retinal complications.
Improved understanding of retinal disease progression in these patients may support earlier intervention and better long-term visual outcomes.
Recognition for Outstanding Contributions to Retina Medicine
The ASRS Annual Meeting will also recognize several RCA-affiliated physicians for their longstanding contributions to vitreoretinal medicine.
Carl C. Awh, MD, FASRS, of Tennessee Retina, will receive the prestigious ASRS Founders Award.
This honor recognizes physicians who have made exceptional contributions to vitreoretinal surgery, retinal disease treatment, scientific research, and patient care throughout their careers.
Receiving the Founders Award represents one of the highest distinctions within the retina specialty and reflects decades of clinical excellence and innovation.
In addition, Joel A. Pearlman, MD, PhD, FASRS, of Retinal Consultants Medical Group, will receive the Packo Award.
The award recognizes individuals who have demonstrated extraordinary service and dedication to the American Society of Retina Specialists and the advancement of the profession.
These honors underscore the significant leadership roles RCA physicians continue to play within the global retina community.
ASRS President Highlights Importance of Clinical Research
Geoffrey G. Emerson, MD, PhD, FASRS, President of the American Society of Retina Specialists and a physician with Retina Consultants of Minnesota, emphasized the importance of the ASRS Annual Meeting as the leading international scientific forum for retina specialists.
He noted that RCA’s extensive scientific participation reflects the commitment shared by physicians across affiliated practices to advancing research aimed at preventing blindness.
According to Emerson, ongoing clinical investigation allows physicians to offer patients access to innovative treatment options closer to home while contributing to scientific discoveries that shape future standards of retina care.
The collaboration among investigators also strengthens the evidence supporting emerging therapies and surgical techniques that may improve outcomes for patients worldwide.
RCA’s Expanding Clinical Research Network
A key factor supporting RCA’s growing research output is its nationwide clinical research infrastructure.
The organization operates one of the largest retina-focused clinical research networks in the United States, with more than 50 research sites participating in Phase I through Phase IV clinical studies.
These research centers collaborate on a broad range of investigator-sponsored and industry-sponsored clinical trials evaluating new pharmaceuticals, medical devices, imaging technologies, surgical techniques, and gene therapies.
By maintaining a centralized research infrastructure, RCA provides participating practices with operational support, regulatory guidance, study coordination, and research resources that enable investigators to conduct high-quality clinical trials.
This collaborative model also expands patient access to innovative investigational treatments that may not otherwise be widely available.
Increasing Access to Clinical Trials
One of RCA’s long-term objectives is to improve patient access to cutting-edge retinal therapies through participation in clinical research.
Many patients with complex retinal diseases face limited treatment options once conventional therapies become less effective.
Clinical trials provide opportunities to evaluate promising investigational treatments while contributing valuable scientific knowledge that may benefit future patients.
By supporting research across numerous practice locations, RCA enables more patients to participate in clinical studies without traveling long distances to major academic medical centers.
This decentralized approach helps accelerate patient enrollment while ensuring broader representation across clinical trial populations.
As retinal diseases continue to represent a major cause of vision impairment worldwide, innovation remains essential for improving diagnosis, treatment, and long-term patient outcomes.
The research being presented by Retina Consultants of America physicians at the ASRS 2026 Annual Meeting highlights advances across multiple areas of retina care, including gene therapy, long-acting biologic treatments, artificial intelligence, surgical innovation, pediatric retinal disorders, ocular oncology, and rare inherited diseases.
With more than 30 scientific presentations, recognition for physician excellence, and one of the nation’s largest retina clinical research networks, RCA continues to strengthen its leadership in advancing vitreoretinal medicine. The organization’s collaborative research efforts are helping shape the future of retinal disease management while expanding access to innovative therapies that have the potential to preserve vision and improve quality of life for patients across the globe.
Source link: https://www.businesswire.com/
